
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant Inc. demonstrates a promising outlook based on its innovative focus on IMVT-1402, an FcRn inhibitor that has shown significant disease-modifying potential in autoimmune diseases like Graves' disease (GD). The reported 81% responder rate during a six-month off-treatment period, comparable to the 70%-80% rate seen during active treatment, indicates the treatment's durability and effectiveness, even among patients unresponsive to traditional therapies. Additionally, the consistent reduction in thyroid-stimulating hormone receptor autoantibodies (TRAb) further supports the therapeutic potential of FcRn blockers, enhancing investor confidence in the company's growth prospects.
Bears say
Immunovant Inc operates as a clinical-stage immunology company focused on developing treatments for autoimmune diseases, notably through its investigational drug IMVT-1402. A concerning aspect of Immunovant's outlook is the association of persistently high TRabs with elevated rates of relapse, signaling potential challenges in clinical efficacy and patient outcomes. Furthermore, the complications arising from TRAbs-mediated TSHR activation, including inflammation and the risk of optic nerve compression, may hinder the therapeutic potential of its product candidates and contribute to overall investor uncertainty.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares